Biotechnology

Antengene's ATG-022 (CLDN18.2 ADC) Granted Breakthrough Therapy Designation for the Treatment of Gastric/Gastroesophageal Junction Adenocarcinoma

SHANGHAI and HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematologic ma...

2025-08-19 13:26 2223

Beyfortus® (nirsevimab) approved in Singapore to protect all infants against RSV disease

* Beyfortus (nirsevimab) is the only option that can offer RSV protection designed for all infants with proven high, sustained efficacy, favourable safety and public health impact demonstrated in the real world.[1] * In the recent HARMONIE trial findings, Beyfortus reduced RSV hospitalisation...

2025-08-19 11:00 3158

RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries

YANTAI, China, Aug. 19, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceutical (China) Co., Ltd. ("Santen China"), a wholly-owned subsidiary o...

2025-08-19 08:00 2660

Avixgen, a subsidiary of Dx&Vx, signs a licensing-out agreement worth USD 360 million with a U.S. biotech company for its next-generation drug delivery platform (ACP).

* This innovative platform technology, with exceptional scalability, has been recognized as highly valuable even with limited rights granted. * DXVX is taking the lead in business development, with several companies in the due diligence stage, and additional deals are anticipated. SEOUL, South...

2025-08-18 21:00 2396

KELUN-BIOTECH ANNOUNCES 2025 INTERIM RESULTS

* Revenue reached approximately RMB950.4 million, with total commercial sales RMB309.8million, representing a significant increase in proportion * Research and development expenses was approximately RMB611.5 million * Loss for the period was RMB145.2 million; adjusted loss for the period[1] ...

2025-08-18 18:29 2900

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY® by the Taiwan Food and Drug Administration for the Treatment of Moderately to Severely Active Ulcerative Colitis

SHANGHAI, Aug. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that the Taiwan Food and Drug Adminis...

2025-08-14 12:02 2743

KBP's Contest of Injunction Obtained by Novo Nordisk Continues in Arbitration

SINGAPORE, Aug. 13, 2025 /PRNewswire/ -- KBP Biosciences Pte. Ltd. (the "Company ") today issued a statement addressing a further decision by the Singapore International Commercial Court (the "Court") to maintain the temporary injunction against the Company and its founder, Dr. Huang Zhenhua ("Dr....

2025-08-13 09:44 5231

WuXi Biologics' WuXiUP™ Accomplishes Automated Continuous Drug Substance Production at Pilot-Scale

* Building on its success in developing continuous production at pilot-scale with the WuXiUP™ platform, WuXi Biologics has further enhanced the technology to achieve automated continuous drug substance (DS) manufacturing at pilot-scale. This advancement integrates industry-leading technologies,...

2025-08-12 17:00 2791

Intas & Accord signs Agreement to acquire Prothya Biosolutions

AHMEDABAD, India, Aug. 11, 2025 /PRNewswire/ -- Accord Plasma B.V., a subsidiary of Intas Pharmaceuticals, has announced the execution of an agreement to acquire 100% of Prothya Biosolutions Belgium BV and each of its subsidiaries, a leading plasma-derived medicinal products (PDMP) business based...

2025-08-11 21:41 3427

Everest Medicines to Announce 2025 Interim Results on August 29, 2025

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim resul...

2025-08-11 17:11 2522

WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules

* WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules. * WuXia293Stable platform maintains stable expression and consistent product quality during long-term c...

2025-08-11 16:30 2840

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

SINGAPORE, Aug. 11, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch ofFibroSIGHT™ Plus, its second Laboratory Developed Test (LDT) available in the United States. Building on the foundation of FibroSIGHT™[1], ...

2025-08-11 09:00 3008

Brain Navi Biotechnology's NaoTrac performs first surgeries in Spain

Brain Navi has officially landed in Spain! TAIPEI, Aug. 11, 2025 /PRNewswire/ -- Such an achievement has been made possible through the first of many collaborations with our valued partner, Palex Healthcare. This milestone has been reached not only thanks to Palex's solid reputation and deep exp...

2025-08-11 09:00 1980

RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA

YANTAI, China, Aug. 8, 2025 /PRNewswire/ -- On August 8th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical trials for its independently-developed bispecific antibody, RC148, for the treatment of multiple ad...

2025-08-08 17:50 2874

Codex Genetics Expands Precision Oncology Portfolio with Cxbladder Genomic Urine Tests

Strategic partnership with Pacific Edge offers Hong Kong clinicians a powerful tool for non-invasive bladder cancer detection and monitoring. HONG KONG, Aug. 8, 2025 /PRNewswire/ -- Codex Genetics, one of the leading precision diagnostics companies inHong Kong, today announced an exclusive colla...

2025-08-08 17:45 2848

WCC Biomedical@NACDS Total Store Expo: Advancing Microneedle Drug Delivery With WINMAP™ Platform

TAIPEI, Aug. 8, 2025 /PRNewswire/ -- WCC Biomedical , a leader in novel drug delivery systems, will attend the upcomingNACDS Total Store Expo (TSE), where it will spotlight its proprietary WINMAP™ microarray patch (MAP) technology and launc...

2025-08-08 09:30 2196

LabConnect Partners with Kits4Life to Reduce Kit Waste and Advance Sustainable Clinical Trials

JOHNSON CITY, Tenn., Aug. 8, 2025 /PRNewswire/ -- As part of our ongoing commitment to environmental stewardship and industry leadership in sustainable clinical research, LabConnect is proud to announce our partnership withKits4Life , an initiative of the MedSurplus Alliance. This collaboration re...

2025-08-08 00:40 2078

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and...

2025-08-07 08:05 4219

New revolutionary brain tech platform 'ScreenIT' puts smarter concussion care in reach

SYDNEY, Aug. 6, 2025 /PRNewswire/ -- A revolutionary new brain health assessment platform,ScreenIT , has officially launched, marking a major step forward in how brain function is monitored, assessed, and optimised across sport, healthcare, and rese...

2025-08-06 06:16 2141

SOPHiA GENETICS expands collaboration with AstraZeneca using AI to improve breast cancer patient outcomes

BOSTON and ROLLE, Switzerland, Aug. 5, 2025 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a global leader in data-driven medicine, today announced an expansion of its partnership with AstraZeneca (LSE/STO/Nasdaq: AZN). This new, multi-year collab...

2025-08-05 18:40 1696
1 ... 26272829303132 ... 185

Week's Top Stories